Antipsychotic Medicine and Metabolic Syndrome

Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00627757

Acronym

AMMS1

Enrollment

100

Registered

2008-03-03

Start date

2008-02-29

Completion date

2010-12-31

Last updated

2010-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

metabolic syndrome, weight gain, antipsychotic drugs, Metabolic syndrome and treatment with antipsychotic drugs

Brief summary

The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life. The investigators expect, that 30-50% of patients will show pharmacon - gene induced weight gain (\> 7% of initial bodyweight) while the rest of patients will maintain unaltered bodyweight.

Detailed description

The primary aim of this study is to investigate status of neuro-and enteroendocrine axes with focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities and inflammations adipokins in patients during treatment with antipsychotics (AP) in relation to weight gain. The second aim is to evaluate the connection between weight gain and patients´ own perception of their quality of life and health.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* gender : male * age: 18-45 * treatment with minimum one Antipsychotic drug (AP) * ethnicity: caucasians * consent given to take part in the project

Exclusion criteria

One criteria is sufficient to exclude patients from the study: * compliance problems * unable to read, write and talk Danish * patients with major lung-,heart-, lever- and kidney problems * patients with diagnose and treatment for Diabetes 1 and 2 * patients taking cholesterol-reducing, weight-reducing and antihypertensive medication * patients with abuse of alcohol or drugs * patients who are under duress § * patients who have been mentally ill for more than 15 years * patients with diagnosis/treatment for NIDDM/IDDM

Countries

Denmark

Contacts

Primary ContactHenrik Lublin, MD DMSc

henlub01@glo.regionh.dk045-43233540

Outcome results